Posted in | News | Uranium

Paladin Posts $29.5 Million Loss

Paladin Energy (ASX: PDN) has seen its first half net loss grow to $29.5 million as the company revised its production forecast.

The sales revenue increased by 14% in the six months ending December 2010 to $114.7 million but the company made a loss of 4.1 cents a share as compared to a 2.9 cents a share loss in the same period in 2009.

The second largest sole uranium mining company in Australia said that it was expecting to produce just 6 to 6.3 million pounds of uranium oxide for the full year till June 30,2011. This is down from the initial production guidance of 7 million pounds.

The loss was correlated to increase in the financial costs of production and a lowering of the gross margin. The financial costs of the quarter were totaled at $ 20.6 million as compared to $ 5.6 million last year. The net loss for the quarter was $ 21.3 million as compared to $ 0.4 million in the corresponding quarter last year.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Paladin Energy Ltd. (2019, March 19). Paladin Posts $29.5 Million Loss. AZoMining. Retrieved on December 14, 2024 from https://www.azomining.com/News.aspx?newsID=3193.

  • MLA

    Paladin Energy Ltd. "Paladin Posts $29.5 Million Loss". AZoMining. 14 December 2024. <https://www.azomining.com/News.aspx?newsID=3193>.

  • Chicago

    Paladin Energy Ltd. "Paladin Posts $29.5 Million Loss". AZoMining. https://www.azomining.com/News.aspx?newsID=3193. (accessed December 14, 2024).

  • Harvard

    Paladin Energy Ltd. 2019. Paladin Posts $29.5 Million Loss. AZoMining, viewed 14 December 2024, https://www.azomining.com/News.aspx?newsID=3193.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.